{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:29:14Z","timestamp":1787225354186,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00160-3","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:09:10Z","timestamp":1787224150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-6832","authenticated-orcid":false,"given":"Hyery","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Nam","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Joon","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"5","key":"160_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.blre.2017.06.002","volume":"31","author":"BL Marini","year":"2017","unstructured":"Marini BL, Perissinotti AJ, Bixby DL, Brown J, Burke PW. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017;31(5):328\u201338.","journal-title":"Blood Rev"},{"issue":"10","key":"160_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/fon-2021-1288","volume":"18","author":"MJ Burke","year":"2022","unstructured":"Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncol. 2022;18(10):1285\u201399.","journal-title":"Future Oncol"},{"key":"160_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.902117","volume":"10","author":"L Maese","year":"2022","unstructured":"Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma. Front Pediatr. 2022;10:902117.","journal-title":"Front Pediatr"},{"issue":"3","key":"160_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2015.137380","volume":"101","author":"IM van der Sluis","year":"2016","unstructured":"van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279\u201385.","journal-title":"Haematologica"},{"issue":"8","key":"160_CR5","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","volume":"56","author":"B Asselin","year":"2015","unstructured":"Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56(8):2273\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"160_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1080\/10428194.2017.1386305","volume":"59","author":"W Salzer","year":"2018","unstructured":"Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797\u2013806.","journal-title":"Leuk Lymphoma"},{"key":"160_CR7","unstructured":"ClinicalTrials.gov. Treatment of newly diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children (SR ALL). Identifier: NCT06099366. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06099366. Accessed 28 Feb 2025."},{"key":"160_CR8","unstructured":"ClinicalTrials.gov. Treatment of newly diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia (HR ALL). Identifier: NCT06184009. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06184009. Accessed 28 Feb 2025."},{"issue":"1","key":"160_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44313-025-00085-3","volume":"60","author":"H Kim","year":"2025","unstructured":"Kim H, Yoon SH, Kang S, et al. Improved survival in pediatric acute lymphoblastic leukemia through therapy intensification based on minimal residual disease and protocol-driven early response risk classification. Blood Res. 2025;60(1):1\u201310.","journal-title":"Blood Res"},{"issue":"3","key":"160_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","volume":"58","author":"MJ Burke","year":"2017","unstructured":"Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58(3):540\u201351.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"160_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"LM Vrooman","year":"2013","unstructured":"Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL Consortium Protocol 00\u201301. J Clin Oncol. 2013;31(9):1202\u201310.","journal-title":"J Clin Oncol"},{"issue":"6","key":"160_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/pbc.25299","volume":"62","author":"A Bleyer","year":"2015","unstructured":"Bleyer A, Asselin BL, Koontz SE, Hunger SP. Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015;62(6):1102\u20135.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"160_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070915","volume":"17","author":"C Matteo","year":"2025","unstructured":"Matteo C, Colombini A, Cancelliere M, et al. Pharmacokinetics of pegaspargase with a limited sampling strategy for asparaginase activity monitoring in children with acute lymphoblastic leukemia. Pharmaceutics. 2025;17(7):915.","journal-title":"Pharmaceutics"},{"issue":"8","key":"160_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27797","volume":"66","author":"SL Cooper","year":"2019","unstructured":"Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797.","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"160_CR15","first-page":"987","volume":"135","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020;135(13):987\u201395.","journal-title":"Blood"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00160-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00160-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00160-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:09:11Z","timestamp":1787224151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00160-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00160-3","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Asan Medical Center (IRB No. 2024\u20131181). Written informed consent was obtained from all participants and\/or their guardians.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"44"}}